Chronic Myelocytic Leukemia
Chronic Myelocytic Leukemia: ORIGIN OF SOME LYMPHOCYTES FROM LEUKEMIC STEM CELLS
... with chronic myelocytic leukemia who were heterozygous at the X-linked glucose-6-phospháte dehydrogenase locus, lymphocytes were studied to determine if they had the same stem cell origin as the ...
10
Autonomous Erythropoiesis during Erythroblastic Crisis of Chronic Myelocytic Leukemia
... conclusions that erythropoiesis was autonomous in this rare syndrome. Three patients with clinical pictures compatible with Di Guglielmo's syndrome were studied as controls. As has been reported previously, ...
5
Leukokinetic Studies X Blood Granulocyte Kinetics in Chronic Myelocytic Leukemia
... DISTRIBUTION OF GRANULOCYTES AS REPRESENTED BY THE RATIO, CIRCULATING GRANULOCYTE POOL TO TOTAL BLOOD GRANULOCYTE POOL CGP/TBGP, IN THE TBGP OF PATIENTS WITH CHRONIC MYELOCYTIC LEUKEMIA [r] ...
14
Isolation of a Novel Glycoprotein from the Urine of a Patient with Chronic Myelocytic Leukemia
... Patient B. J. with chronic myelocytic leukemia excreted 0.5-1.1 g protein per day in the urine. Gel filtration on Sephadex G-75 showed about one-third of this protein to be in molecular weight range ...
8
The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia
... mutation in the coding sequence of the gene. Alterations of the p53 gene were found in the myeloid and the rare megakaryocytic variant of blast crisis but were absent in the lymphoid leukemic transformants. Gross ...
7
Population level survival of patients with chronic myelocytic leukemia in Germany compared to the US in the early 21st century
... Treatment for CML has changed substantially over the first few years of the 21 st century. Until 2001, the stand- ard treatment for CML was hematopoietic stem cell transplant, if possible, and interferon-α with hydroxy- ...
7
Studies of leukocyte kinetics by liquid scintillation counting in normal individuals and in patients with chronic myelocytic leukemia
... = standard deviation of spleen sojourn time, i day; T = mean decay time for cells initially labeled in the peripheral blood, 2 days; 0 = mean sojourn time in the peripheral blood, 0.8 da[r] ...
13
Chronic Myelocytic Leukemia Terminating in Blast Cell Crisis with Lymphoblastic Characteristics
... in lymphoblast cell lines and in blast cells of some patients with chronic inyelogenous leukemia in acute phase. McCaffrey R, Harrison TA, Parkman R, Baltimore D: Terminal deoxynucleotid[r] ...
8
Studies on N5 methyltetrahydrofolate homocystein methyltransferase in normal and leukemia leukocytes
... leukocytes enzymes resembled those of methyltransferases previously studied in bacteria and other animal cells. Granulocytes and chronic myelocytic leukemia cells contain a factor or factors that ...
10
THE GLYCOGEN CONTENT OF HUMAN LEUKOCYTES IN HEALTH AND IN VARIOUS DISEASE STATES
... On the other hand, the low glycogen content of myeloid leukocytes in chronic myelocytic leukemia appears to be a consistent metabolic aberration in this disease while in polycythemia ver[r] ...
8
SETBP1 mutations as a biomarker for myelodysplasia /myeloproliferative neoplasm overlap syndrome
... 26. Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Dohner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum ...
5
Arsenic trioxide exerts synergistic effects with cisplatin on non-small cell lung cancer cells via apoptosis induction
... Since lung cancer is a lethal disease due to late detection and resistance to chemotherapy, this study was conducted to determine whether As 2 O 3 could exert synergistic effects in combination with traditional ...
8
Individualizing kinase targeted cancer therapy: the paradigm of chronic myeloid leukemia
... the leukemia cells to adequately replace a large multi-domain protein with alternative signaling pathways, driving resistance toward BCR-ABL1 muta- tional escape ...
11
SRSF2 mutations in myelodysplasia/myeloproliferative neoplasms
... An international cohort study showed poor OS outcomes associated with the SRSF2 mutations in CMML patients aged ≤ 65 years but with non-significant difference among leukemic transformation rates [57]. Similar outcomes ...
7
BIRC5 Gene Disruption via CRISPR/Cas9n Platform Suppress Acute Myelocytic Leukemia Progression
... Profound expression of survivin in leukemic cells versus absence in normal differentiated adult cells highlight the biological importance of this oncoprotein in the biology of leukemia [11-13] . Beyond that, a ...
10
Molecular genetics of chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia
... including chronic myeloid leukemia (CML), poly- cythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF) which have different molecular abnormalities including mutations in Janus ...
7
Droplet digital PCR for the quantification of Alu methylation status in hematological malignancies
... In the era of cancer epigenetics, Alu methylation in- vestigation may be important not only to evaluate the global DNA methylation variations in disease, and the impact of Alu epigenetic variations on gene expression and ...
11
The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017)
... In chronic lymphocytic leukemia (CLL), molecular characterization by high-throughput technologies are redefining risk groups and paving the way for truly individualized treat- ment strategies, based on the ...
10
Superwarfarin Poisoning in Children: A Prospective Study
... Acute myelocytic leukemia was diag- nosed 2 months postingestion in a 4-year-old child who ingested an unknown amount and had a 1.08 prothrombin time ratio 24 hours after ingestion (no f[r] ...
7